ACADIA Pharmaceuticals (ACAD) Shares are Up 1.34%

ACADIA Pharmaceuticals (ACAD) : Traders are bullish on ACADIA Pharmaceuticals (ACAD) as it has outperformed the S&P 500 by a wide margin of 4.63% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.41%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.34% in the last 1 week, and is up 8.15% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 7.56% and the 50-Day Moving Average is 4.87%. ACADIA Pharmaceuticals Inc. is up 14.67% in the last 3-month period. Year-to-Date the stock performance stands at 3.9%.


ACADIA Pharmaceuticals (NASDAQ:ACAD): stock turned positive on Friday. Though the stock opened at $36.62, the bulls momentum made the stock top out at $37.2 level for the day. The stock recorded a low of $35.91 and closed the trading day at $37.04, in the green by 0.82%. The total traded volume for the day was 1,210,818. The stock had closed at $36.74 in the previous days trading.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.